Purpose Chronic arsenic exposure at levels found in US drinking water has been associated with bladder cancer. While arsenic is a known carcinogen, recent studies suggest that it is useful as a therapeutic agent for leukemia. This study examined the relationship between arsenic exposure and bladder cancer mortality. Methods We studied 832 cases of bladder cancer diagnosed in New Hampshire from a population-based case-control study. Individual exposure to arsenic was determined in home drinking water using ICP-MS and in toenail samples by instrumental neutron activation analysis. Results Among the high arsenic exposure group, found using toenail arsenic level or arsenic consumption, cases experienced a de-escalated survival hazard ratio (HR) [high (¸75 percent) versus low (<25th percentile) toenail arsenic overall survival HR 0.5 (95% CI 0.4-0.8)], controlled for tumor stage, grade, gender, age and treatment regimen.
Introduction
Arsenic is a common trace element present in groundwater in varying amounts across the US. While arsenic is an established bladder carcinogen, the inXuence of this arsenic exposure on the prognosis for patients with bladder cancer remains to be elucidated. Chronic exposure to arsenic through drinking water occurs in several regions of the US, particularly the northeast and southwest. Approximately 2% of the drinking water serving US households contains 2 g/L arsenic or more [1] , primarily the result of geologic contamination. Approximately, 40% of households in New Hampshire are served by un-regulated privately supplied drinking water wells [2, 3] .
Although arsenic's mechanism of action remains under investigation, it induces apoptosis, inhibits cell proliferation, and modulates immune function and angiogenesis [4] [5] [6] . Medicinal use of arsenic was common historically; however, in 1992, inorganic trivalent arsenic, in the form of arsenic trioxide (ATO), induced complete acute promyelocytic leukemia (APL) remission in over two-thirds of patients enrolled in a clinical trial [7] . Similar eVects were also demonstrated for multiple myeloma and lymphoma [8] . The clinical activity of arsenic in solid tumors, including transitional cell carcinoma of the bladder, is being evaluated [9] [10] [11] .
Thus, we investigated the relationship between inorganic arsenic exposure from contaminated drinking water and bladder cancer survival using a large, population-based study of 832 cases diagnosed in New Hampshire, USA. Household drinking water arsenic levels were assessed and toenail arsenic was used as an individualized internal biomarker of exposure. We hypothesized that the arsenic exposure may impact survival rates. We also considered whether the TP53 status of the tumors was related to survival and arsenic exposure. TP53 protein levels are positively associated with tumor grade and stage for invasive tumors [12, 13] . Mutations in the TP53 gene result in the production of a non-functional protein with an abnormally long half-life [14] .
Methods

Study group
BrieXy, we identiWed all cases of bladder cancer diagnosed among New Hampshire residents, ages 25-74 years, from 1 July, 1994 to 31 December, 2001 from the state cancer registry and interviewed a total of 832 bladder cancer cases, which was 85% of the cases conWrmed to be eligible for the study. Tumor tissue samples were re-reviewed by the study pathologist to assess tumor histology, stage and grade. The stage assigned by the pathologist was used for tumors <stage 2A, while cancer registry data were used for higher stage. Treatment and size data were obtained from the state cancer registry. Death of cases was determined as of 15 June, 2009 using the Social Security and the National Death Indices (NDI). The NDI-Plus service was used to assign bladder cancer as the cause of death. Due to the lag in the release of NDI data, cause of death information was available only on cases that died prior to 2006. Of the 298 total deaths among the cases, 87 can currently be speciWcally attributed to bladder cancer. Death from other causes or death from a cause that is currently unknown were excluded for the analysis of bladder cancer cause-speciWc mortality. The median duration of follow-up was 9.3 years.
Personal interview
Informed consent was obtained from each participant, and all procedures and study materials were approved by the Committee for the Protection of Human Subjects at Dartmouth College. Consenting participants underwent a detailed in-person interview covering sociodemographic information and lifestyle factors such as the use of tobacco.
Arsenic analysis
Samples of toenail clipping collected at the time of interview were analyzed for arsenic and other trace elements by instrumental neutron activation analysis (INAA) at the University of Missouri Research Reactor, using a standard comparison approach as described previously [2] . The detection limit for arsenic measured by INAA is approximately 0.001 mg/g.
Water samples from the current household drinking water were drawn into two mineral free bottles (I-Chem) with strict precautions taken to avoid contamination. Samples of drinking water were analyzed for arsenic concentration using an Agilent 7500c Octopole ICPMS in the Dartmouth Trace Element Analysis Core Facility. The intraclass correlation between replicate (masked) samples was 0.98 down to concentrations of 0.010 g/L or less [15] . Groups were created for high versus low arsenic exposure analyses using the 75th percentile as a cutoV, which is a toenail arsenic level of 0.12 g/g, or 0.74 g/L in the household drinking water. Low arsenic exposure was used as the reference group (·25th or 0.057 g/g toenail, 0.11 g/L drinking water). We also considered the eVects by dose (90th percentile: >0.2 g/g toenail, 50th: >0.081 g/g toenail, 25th: >0.057 g/g toenail). In addition, we analyzed drinking water arsenic using the current US maximum contaminant level (MCL) for drinking water (10 g/L) as a cutoV. Arsenic consumption was calculated by multiplying the drinking water arsenic concentration at home by the number of glasses the subject reported consuming from that water source in the questionnaire.
Immunohistochemistry and mutational analysis
Immunohistochemical staining of paraYn-embedded slides was performed to assess TP53 protein levels in tumor tissue. BrieXy, slides were deparaYnized and hydrated into water followed by antigen retrieval. Staining of p53 was performed using a monoclonal antibody (BioGenex, San Ramon, CA, USA) at a 1:100 dilution. The staining was scored by a trained pathologist (percentage of cells, intensity: negative, 1, 2, 3+). Immunohistochemical data for p53 were available on 627 cases and 163 tumors had high staining intensity, classiWed as ¸3+ staining. Mutational analysis of TP53 exons 5 through 9 was available in a subset of 389 bladder tumor samples (33 subjects of these subjects had identiWed mutations) [16] .
Statistical analysis
Survival analysis for bladder cancer cases was performed using Kaplan-Meier (KM) plots. DiVerences between groups were assessed using the log-rank test. To adjust for additional factors related to patient survival, Cox-proportional hazards regression analysis was performed with age, gender, smoking status (never, former, and current), as well as AJCC T/N/M tumor stage (0, Cis, I, II, III, and IV), tumor grade (1, 2, and 3), tumor size and treatment (surgery, chemotherapy/radiation, and immunotherapy) in the model. Statistical signiWcances of interactions were assessed using likelihood ratio tests comparing the models with and without interaction terms. P values represent twosided statistical tests with statistical signiWcance at P < 0.05.
Results
Demographic characteristics of the study populations are shown in Table 1 . Subjects tended to be mainly Caucasian with a mean age of 62 years and a large proportion were males. Our analyses were not appreciably altered by restricting to Caucasians. In our population-based study, 75% of the participants had stage Ta or T1 tumors, and 12% had stage T2 or higher. The median survival time for these groups was 8 and 6 years, respectively. At the time of their diagnosis, 33% of the cases were current smokers.
As shown in Table 2 , the Cox-regression analysis comparing high arsenic exposure (>75th percentile) to the low exposure, grouped by toenail arsenic level (·25th), exhibited a signiWcant hazard ratio (HR) of 0.5 (95% CI 0.4-0.8) indicating a prolonged overall survival associated with arsenic exposure after adjustment for age, sex, smoking status, stage, grade and therapy. High toenail arsenic levels were related to better overall survival in a dose-responsive manner (p-trend = 0.004) (Log-rank p value < 0.001) ( Fig. 1a; Table 2 ). Cox-regression analysis using high versus low arsenic consumption showed a similar trend of HR 0.7 (95% CI 0.5-1.1). There was also a suggestion of slightly improved survival with household drinking water arsenic level above the current US MCL (>10 g/L), compared to lower levels, but with wide conWdence intervals [HR 0.7 (95% CI 0.3-1.5)]. Similar trends were observed for bladder cancer cause-speciWc survival, but the results were not statistically signiWcant. Toenail arsenic levels >75th were associated with longer survival HR 0.5 (95% CI 0.3-1.1) compared to low arsenic level (<25th).
The eVect of high (>75th) versus low (<25th) toenail arsenic level on overall survival did not diVer strongly between non-invasive [HR 0.5 (95% CI 0.3-0. Fig. 1b) . Logistic regression analysis with adjustment for age, gender and smoking showed that high toenail arsenic levels (>75th) decreased the odds of being diagnosed with a tumor of stage I or higher [OR 0.7 (95% CI 0.5-0.9)] compared to having low (<25th) arsenic exposure.
We have previously observed that less TP53 immunohistochemical staining is associated with better overall survival [17] and that arsenic exposure was related to less TP53 staining and a lower prevalence of p53 mutations. The diVerence in survival was consistent within both the high and low TP53 intensity groups, and remained when we included adjustment for TP53 intensity [overall survival HR 0.5 (95% CI 0.3-0.7); bladder cancer-speciWc HR 0.5 (0.2-1.0)] or TP53 mutations [overall survival HR 0.4 
Discussion
Arsenic is an old remedy that has been resurrected due to recently discovered eYcacy in acute promyelocytic leukemia, multiple myelomas, lymphomas, pancreatic cancer cell lines and prostate cancer tissue [18] , and has been proposed as a treatment for bladder and other epithelial cancers [9] [10] [11] . Our study addressed the hypothesis that environmental arsenic exposure might be related to the survival of patients with bladder cancer.
The results suggest that there is a decreased risk of overall death for patients exposed to higher amounts of arsenic, with a non-signiWcant similar trend for cause-speciWc mortality. Explanations for this observation are: (a) the biology of arsenic-related tumors may diVer, (b) arsenic may directly aVect tumor growth or (c) arsenic may interact with cancer treatments [6] . Our data suggest that arsenic exposure may modify the biology of the tumor development as high arsenic exposure is associated with less aggressive tumors.
We previously reported that there was a lower incidence of TP53 mutations and over-expression in patients exposed to arsenic [16] . These factors are associated with poor prognosis and could explain our Wndings [17] . As an alternative explanation, arsenic induces epidermal growth factor receptor (EGFR) activation [19] . EGFR-driven tumors show better response to treatment than other types of tumors (reviewed in [20] ).
Recent ecologic studies have explored the relationship between arsenic and bladder cancer survival. Hospitalbased Taiwanese studies of transitional cell carcinoma of the urinary bladder found a higher proportion of females, higher grade/stage tumors and a lower 5-year survival rate for subjects living in the area with endemic blackfoot's disease (¸350 g/L), compared with other areas (<350 g/L), but there was no association between arsenic exposure zone and survival time [21, 22] . Potentially confounding diVerences include gender, stage, delayed diagnosis, emigration, occupation and socioeconomic status between the exposure zones. Our population-based observational US study assessed a lower range of arsenic exposure using individualized exposure biomarker measurements within a single geographic area.
Use of arsenic as an anticancer agent in epithelial cells, including bladder, has been shown to be eVective in combination with glutathione synthesis inhibition [10, 23] . Although the exact mechanism of action is still unclear, a majority of arsenic-induced acute promyelocytic leukemia responses occur by activating apoptosis [24] . Arsenic can destabilize lysosomes, degrading the PML/RAR protein [25] and inhibiting proliferation via p21 [26] . While these studies suggest a therapeutic role for arsenic in cancer, others highlight the serious deleterious toxicities and side eVects of arsenic, including the possibility of treatment-related secondary malignancies [27] , cardiovascular diseases, enhanced angiogenesis and vascular remodeling [28] . Arsenic also initiates defenestration and capillarization of the liver sinusoidal endothelial cells and may impair the cellular immune response [29, 30] .
Limitations of our study include a small number of highly exposed individuals. Arsenic measurements from household drinking water do not include arsenic from workplace or other sources of water consumption. Toenail arsenic serves as a biologic indicator of arsenic exposure integrating all sources of exposure and metabolic diVerences between individuals. We have included overall and cause-speciWc mortality for bladder cancer cases. Cause of death is known to be problematic, as inconsistent methods are used in assigning cause of death on death certiWcates.
In summary, we found that bladder cancer patients exposed to higher levels of arsenic had a better survival rate than those with low exposure. Further research is needed to determine whether our observation is due to the etiologic eVect of arsenic on the underlying biology of the tumors, a direct eVect of continued arsenic exposure on tumor growth or a synergistic eVect of continued arsenic exposure combined with treatment. Our results are consistent with the beneWcial outcome in patients with an epithelial malignancy and highlight the need for further studies of arsenic exposure in bladder and other epithelial cancers to elucidate the mechanism by which arsenic is associated with bladder cancer survival. 
